The Alpha Journal — Men’s Health Reporting

Brain fog is not listed as an adverse effect in the FDA prescribing information for either Mounjaro or Zepbound — but that doesn't mean patients never experience it.

Tongkat ali (Eurycoma longifolia) produces measurable increases in testosterone and libido in men who start with low or suppressed levels — the evidence for that is solid enough to take seriously.

Retatrutide produces roughly twice the weight loss of Wegovy in clinical trials — approximately 24–29% body weight reduction versus 14.9% for semaglutide 2.4 mg weekly — making it the most potent obesity pharmacotherapy tested in a phase 3 setting to date.

Sildenafil not working doesn't mean you're out of options — it often means you haven't found the right option yet. Research consistently shows that 25–35% of men report inadequate response to Viagra, but a large fraction of those are fixable with better technique, a different…

Zepbound and compounded tirzepatide contain the same active molecule, but that's roughly where the equivalence ends. The practical differences — in quality assurance, dosing reliability, safety documentation, and cost — are substantial enough to matter clinically.

Low testosterone and normal aging share enough symptoms to confuse both patients and clinicians — but the distinction matters because treating age-related decline as pathological hypogonadism leads to unnecessary hormone therapy.

Brand-name Wegovy has a robust clinical record; compounded semaglutide is cheaper but carries real manufacturing and dosing risks that the FDA has formally documented.

Finasteride is the proven standard for male androgenetic alopecia (AGA), backed by decades of randomized trial data — but pyrilutamide (KX-826) is emerging as a credible topical alternative that blocks androgen receptors locally without suppressing systemic DHT.

Semaglutide has the stronger cardiovascular outcomes evidence right now — full stop. But tirzepatide produces greater weight loss and broader cardiometabolic improvements, and the gap in hard-endpoint data is narrowing fast.